Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Eli Lilly and Company (LLY) stocks

Learn how to easily invest in Eli Lilly and Company stocks.

Eli Lilly and Company is a drug manufacturers-general business based in the US. Eli Lilly and Company stocks (LLY.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $312.72 – an increase of 7.5% over the previous week. Eli Lilly and Company employs 35,000 staff and has a trailing 12-month revenue of around $29.3 billion.

How to buy stocks in Eli Lilly and Company

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LLY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Eli Lilly and Company stock price (NYSE:LLY)

Use our graph to track the performance of LLY stocks over time.

Eli Lilly and Company shares at a glance

Information last updated 2022-06-24.
Latest market close$312.72
52-week range$217.85 - $324.08
50-day moving average $297.63
200-day moving average $265.68
Wall St. target price$304.28
PE ratio 46.4804
Dividend yield $3.53 (1.32%)
Earnings per share (TTM) $6.73

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99–$9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple Trade account and fund at least $150.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Eli Lilly and Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Eli Lilly and Company price performance over time

Historical closes compared with the close of $312.72 from 2022-06-23

1 week (2022-06-17) 7.50%
1 month (2022-05-25) 1.86%
3 months (2022-03-25) 8.20%
6 months (2021-12-21) N/A
1 year (2021-06-25) 35.84%
2 years (2020-06-25) 92.02%
3 years (2019-06-25) 171.08%
5 years (2017-06-23) 272.77%

Is Eli Lilly and Company under- or over-valued?

Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly and Company's P/E ratio

Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Eli Lilly and Company shares trade at around 46x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Eli Lilly and Company's PEG ratio

Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8841. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eli Lilly and Company's EBITDA

Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.7 billion.

The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.

Eli Lilly and Company financials

Revenue TTM $29.3 billion
Operating margin TTM 30.99%
Gross profit TTM $21.3 billion
Return on assets TTM 12.12%
Return on equity TTM 74.02%
Profit margin 20.9%
Book value $10.37
Market capitalisation $297.1 billion

TTM: trailing 12 months

Eli Lilly and Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Eli Lilly and Company's total ESG risk score

Total ESG risk: 32.36

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 01/01/2019) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Eli Lilly and Company's environmental score

Environmental score: 0.63/100

Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Eli Lilly and Company's social score

Social score: 16.68/100

Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Eli Lilly and Company's governance score

Governance score: 13.31/100

Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Eli Lilly and Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.

Eli Lilly and Company share dividends

41%

Dividend payout ratio: 41.03% of net profits

Recently Eli Lilly and Company has paid out, on average, around 41.03% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.32% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 1.32% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $3.53 per share.

While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.

Eli Lilly and Company's most recent dividend payout was on 10 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 May 2022 (the "ex-dividend date").

Have Eli Lilly and Company's shares ever split?

Eli Lilly and Company's shares were split on a 2:1 basis on 16 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.

Eli Lilly and Company share price volatility

Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $217.8462 up to $324.08. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.3975. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).

Eli Lilly and Company overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site